NovaBay Pharmaceuticals to Hold First Quarter 2022 Conference Call on May 12May 05, 2022 at 06:50 AM EDT
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three months ended March 31, 2022 after market close on Thursday, May 12, 2022 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.
The live webcast of the conference call also will be available at http://novabay.com/investors/events. A replay of the call will be available beginning two hours after its completion through June 2, 2022 by dialing 877-344-7529 from within the U.S., 855-669-9658 from Canada or 412-317-0088 from outside the U.S., and entering conference ID 9711049. The webcast will also be archived at http://novabay.com/investors/events. About NovaBay Pharmaceuticals, Inc: NovaBay Pharmaceuticals, Inc. is a pharmaceutical company that develops and sells scientifically created and clinically proven consumer products for the eyecare and skincare markets. Avenova® is the most prescribed antimicrobial lid and lash spray in the eyecare market. In November 2021, NovaBay acquired DERMAdoctor, LLC, a company offering more than 30 dermatologist-developed skincare products sold through traditional domestic retailers, digital beauty channels and international distributors. Socialize and Stay Informed on NovaBay’s Progress
Like us on Facebook
Avenova Purchasing Information
For NovaBay Avenova purchasing information:
DERMAdoctor Purchasing Information
For DERMAdoctor purchasing information:
View source version on businesswire.com: https://www.businesswire.com/news/home/20220505005162/en/ Contacts
NovaBay Contact
Investor Contact
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|
Stock Quote
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|